Study reveals MASLD, MetALD responsible for one-third of ICU cirrhosis cases

Metabolic dysfunction-associated steatotic liver disease (MASLD)-related and metabolic and alcohol-related liver disease (MetALD)-related cirrhosis is responsible for one-third of cirrhosis cases seen in the intensive care unit (ICU), according to a study published online July 22 in Alimentary Pharmacology and Therapeutics.

Philippe Sultanik, M.D., Ph.D., from Sorbonne Université in Paris, and colleagues assessed the prevalence of MASLD-related cirrhosis in the ICU (January 2019 to September 2021) among 315 patients (39 with MASLD, 160 with alcohol-related liver disease [ALD], and 116 with MetALD cirrhosis).

The researchers found that patients in the MASLD group were significantly older (65 years versus 57 and 59 years, respectively) and had lower Child-Pugh (8 versus 11 and 10, respectively) and Model for End-Stage Liver Disease scores (17 versus 22 and 21, respectively). There were no differences in one-year transplant-free survival between the groups (53% versus 54 and 54%, respectively).

All groups had cardiovascular mortality of less than 5%. The MASLD group had a significantly higher one-year probability of developing hepatic encephalopathy (73% versus 27 and 21%, respectively).

“MASLD or MetALD was responsible for one-third of the causes of cirrhosis in the ICU,” the authors write. “MASLD-related cirrhosis is as severe as ALD-related cirrhosis. Liver transplantation should be rapidly discussed.”

© 2024 HealthDay. All rights reserved.